Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Postmenopausal South Korean Women With Osteoporosis

NCT02791516 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02791516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02791516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Postmenopausal South Korean Women With Osteoporosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
January 16, 2017
Completion date
December 21, 2018
Enrollment
67 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis